New Clinical Standards in Biliary Cancer Management
Key Summary:
- Surgical resection remains the only curative approach, requiring six months of adjuvant capecitabine.
- Reflex molecular testing with next-generation sequencing is recommended to guide actionable targeted therapy.
- Frontline standard of care combines cisplatin and gemcitabine with durvalumab or pembrolizumab immunotherapy
INTERNATIONAL specialists have established new clinical guidance to optimize modern cholangiocarcinoma management and enhance patient outcomes. Arising from bile duct epithelia, cholangiocarcinoma represents an increasingly prevalent malignancy worldwide, historically characterized by late stage detection and poor survival rates. To counter persistent clinical hurdles, an international expert panel generated evidence-based recommendations and strategic priorities spanning classification, biomarker implementation, and therapeutic intervention.
Standardizing Classification and Cholangiocarcinoma Management
Adopting precise anatomical classification under ICD-11 serves as an essential foundation for distinguishing intrahepatic, perihilar, and distal disease subtypes. Surgical resection remains the solitary curative-intent option, yet it is viable in only 20% to 30% of newly diagnosed cases, mandating six months of adjuvant capecitabine to curb high recurrence rates. For unresectable lesions, early identification of candidates eligible for liver transplantation or locoregional therapies offers critical survival advantages. Multidisciplinary tumor boards are strongly recommended for every patient to navigate complex cholangiocarcinoma management pathways effectively.
Genomic Profiling and Next-Generation Therapies
Comprehensive molecular profiling via next-generation sequencing is now standard clinical practice for all advanced cases to direct individualized targeted therapy. Actionable oncogenic drivers, including IDH1 mutations, FGFR2 fusions, HER2 amplifications, and BRAF mutations, provide proven targets for approved systemic agents. For first-line palliative care, combining cisplatin and gemcitabine with immune-checkpoint inhibitors, such as durvalumab or pembrolizumab, significantly improves survival over chemotherapy alone. When actionable alterations are absent, second-line FOLFOX remains the preferred evidence-based option following disease progression.
Sustaining Innovation in Biliary Oncology
Closing enduring clinical gaps requires rapid validation of novel liquid biopsy platforms, expanded clinical trial accrual, and dedicated exploration of the complex tumor immune microenvironment. Refining cholangiocarcinoma management further relies on overcoming acquired drug resistance mechanisms through novel combinations and proactive supportive care protocols.
This landmark consensus statement also honors the enduring clinical legacy of coauthor Dr. Rachna Shroff, whose pioneering leadership transformed modern biliary cancer clinical trials. Her vision continues through the Conquer Cancer Rachna Shroff, MD, MS, FASCO Endowed Young Investigator Award, funding promising early-career researchers dedicated to conquering biliary tract cancers.